AGENDA

 

Session I

Moderators: Sami Alshamari, Abrar Khojah, Emad Azhari

18:20 –18:00
Palliative Sedation

Palliative Sedation

Dr. Mohammed Abosoudah

18:20-18:40
Common errors in opioid prescription

Common errors in opioid prescription

Dr. Taher Karriri

18:40-19:00
Methadone in Palliative patients

Methadone in Palliative patients

Dr. Nabil Al Moalami

19:00-19:15

Break

Session II

Moderators: Ahmed bin Ahmed, Hafez Ghanem, Rami Faraj

19:15-19:35
Palliative Care burden avoidance in emergency

Palliative Care burden avoidance in emergency

Dr. Eman Bukhari

19:35-19:55
Managing Fatigue in Palliative Care

Managing Fatigue in Palliative Care

Dr. Waleed Bukhari

19:55- 21.15
A Difficult Pain (case presentation)

A Difficult Pain (case presentation)

Dr. Rawabi Shaikh

21:15-20:30

Discussion

Session I : GU cancers

9:00 –9:15
Role of Adjuvant therapy post nephrectomy

Role of Adjuvant therapy post nephrectomy

Dr. Ahmed Alrefaee

9:15-9:30
1st line systemic therapy in advanced RCC

1st line systemic therapy in advanced RCC

Dr. Guillermo de Velasco

9:30-9:45
first line therapy in advanced bladder cancer: recent advances and challenges

first line therapy in advanced bladder cancer: recent advances and challenges

Dr. Rula Almufti

9:45 -10:00
Best therapy for mCRPC  chemotherapy versus novel antiandrogens

Best therapy for mCRPC chemotherapy versus novel antiandrogens

Mubarak Almansour

10:00-10:15
Systemic therapy for castration sensitive metastatic prostate cancer doublet versus Triplet

Systemic therapy for castration sensitive metastatic prostate cancer doublet versus Triplet

Dr. Emad Tashkandi

10:15-10:30
Precision medicine in advanced mCRPC

Precision medicine in advanced mCRPC

Dr. Abdullah Alsharm

10:30 -10:50

Panel Discussion:

Panel Discussion:

Moderator:  Hani Elkhatib, Faisal Albadainah

Panel:

Ahmed Alrefae,   Guillermo de Velasco,

Rula Almufti, Mubarak Almansour,  , Abdullah Alsharm

10:50-13:30

Prayer& Lunch

Session II : Breast Cancer (HR+/HER2-)

14:00-14:20
Treatment options after CDK4/6 inhibitors in advanced breast cancer in 2022: Hormonal/chemotherapy/ADC

Treatment options after CDK4/6 inhibitors in advanced breast cancer in 2022: Hormonal/chemotherapy/ADC

Dr. Antonio Llombart

14:20-14:40
Molecular tools and extended adjuvant hormonal therapy in in HR+/HER2-negative breast cancer

Molecular tools and extended adjuvant hormonal therapy in in HR+/HER2-negative breast cancer

Dr. Hamdy Abdelazim

14:40-15:00
Clinical implications ADCs in Advanced HER2- positive breast cancer: treatment impact and how to sequence

Clinical implications ADCs in Advanced HER2- positive breast cancer: treatment impact and how to sequence

Dr. Adher Alsayed

15:00-15:20
Immune therapy in early TNBC: What we know/What we do not know?

Immune therapy in early TNBC: What we know/What we do not know?

Dr. Omelkhair Abulkhair

15:20-15:40

Discussion

Discussion

Moderators:  Shereef Elsamany 

Panel:  ,    Hamdy Abdelazim,  Ahmed Alwabari, Omalkhair Abulkhair,  Adher Alsayed,  Antonio Llombart

15:40-16:00

Break& prayer

Session III : Take home message (Metastatic Breast cancer)

16:00-16:20
Treatment of brain metastasis in HER2+ve breast cancer: can we omit local therapy?

Treatment of brain metastasis in HER2+ve breast cancer: can we omit local therapy?

Dr. Meteb Alfoheidi

16:20-16:40
Is there a role for local therapy in oligometastatic BC

Is there a role for local therapy in oligometastatic BC

Dr. Guillermo de Velasco

16:40-17:00
When to stop maintenance trastuzumab/pertuzumab in metastatic HER2+ BC?

When to stop maintenance trastuzumab/pertuzumab in metastatic HER2+ BC?

Dr. Essam Murshid

17:00-17:20
PARPi vs platinum in BRCA-mutant advanced TNBC

PARPi vs platinum in BRCA-mutant advanced TNBC

Dr. Hesham Alghazali

17:20-17:40

Discussion

Moderator: Ahmed Saadeldin

Panel:  Meteb Alfoheidi, Essam Murshid,   Guillermo de Velasco, Hamdy Abdelazim

17:40-18:00

Break

Take Home Message Session (Early Breast Cancer)

18:00-18:20
Adjuvant anti HER2 therapy in patients with pCR: trastuzumab or trastuzumab+pertuzumab?

Adjuvant anti HER2 therapy in patients with pCR: trastuzumab or trastuzumab+pertuzumab?

Dr. Sameh Shamaa

18:20-18:40
Adjuvant therapy in TNBC with residual disease post NAC: capecitabine, pembrolizumab, olaparib or in combination

Adjuvant therapy in TNBC with residual disease post NAC: capecitabine, pembrolizumab, olaparib or in combination

Dr. Antonio Llombart

18:40-19:00
Adjuvant therapy in high risk HR+/HER2-negative BC:olaparib/abemaciclib or both?

Adjuvant therapy in high risk HR+/HER2-negative BC:olaparib/abemaciclib or both?

Dr. Ahmed Alshehri

19:00-19:20
Omitting adjuvant chemotherapy in selected population with Luminal breast cancer: N1, lobular, T3N0

Omitting adjuvant chemotherapy in selected population with Luminal breast cancer: N1, lobular, T3N0

Dr. Adher Alsayed

19:20-19:40

Discussion

Moderator: Bassam Basuliman

Panel:   Sameh Shamaa,  Antonio Llombart,   Adher Alsayed,  Omalkhair Abulkhair

Session I: GI cancers I

09:30-09:50
Perioperative therapy in adenocarcinoma of esophagus: How to make treatment choice?

Perioperative therapy in adenocarcinoma of esophagus: How to make treatment choice?

Dr. Shouki Bazarbashi

09:50-10:10
Immune therapy in 1st line gastric/esophageal cancer: which agent/patient?

Immune therapy in 1st line gastric/esophageal cancer: which agent/patient?

Dr. Marwan Alhejeeli

10:10-10:30
ctDNA in early CRC: is it the prime time to go?

ctDNA in early CRC: is it the prime time to go?

Mubarak Almansour

10:30-10:50
RAS-wild metastatic CRC: Best strategy, treatment sequence and chemotherapy backbone?

RAS-wild metastatic CRC: Best strategy, treatment sequence and chemotherapy backbone?

Dr. Fahed Ibn Shamsa

10:50-11:10

Panel discussion

Moderator: Shadi Khayat

Panel:  Mohammed Shouki Bazarbashi, Marwan Alhejeeli ,  Mubarak Almansour,  Fahed Ibn Shams

11:10-11:30

Break

Session II: GI cancers II

11:30-11:50
Immune therapy in early CRC: challenges and opportunities

Immune therapy in early CRC: challenges and opportunities

Dr. Ahmed Alshehri

11:50-12:10
 Immune therapy in advanced CRC: How to refine therapeutic outcome?

Immune therapy in advanced CRC: How to refine therapeutic outcome?

Dr. Mohamed Alghamdi

12:10 - 12:30
Is there a role for neoadjuvant chemoradiotherapy in locally advanced (unresectable/borderline resectable) pancreatic cancer

Is there a role for neoadjuvant chemoradiotherapy in locally advanced (unresectable/borderline resectable) pancreatic cancer

Dr. Emad Tashkandi

2:30 - 12:50
Neoadjuvant therapy in resectable pancreatic cancer: Role and limitations?

Neoadjuvant therapy in resectable pancreatic cancer: Role and limitations?

Dr. Mohamed Awad

12:50 - 13:10

Panel discussion

Moderator: Jamal Zekri

Panel:  Ahmed Alshehri,  Mohamed Alghamdi,  Emad Tashkandi, Mohamed Awad

Session III: hepatobiliary cancers

13:10 - 13:30
1st line therapy in advanced HCC: how to make treatment decision in 2022?

1st line therapy in advanced HCC: how to make treatment decision in 2022?

Dr. Fahed Ibn Shamsa

13:30-13:50
How to sequence systemic therapies after 1st line immunetherapy in advanced HCC

How to sequence systemic therapies after 1st line immunetherapy in advanced HCC

Dr. Kanaan Alshemari

13:50-14:10
Is chemotherapy+durvalumab the new standard of care in advanced BTC?

Is chemotherapy+durvalumab the new standard of care in advanced BTC?

Dr. Ashwaq Aolayan

14:10-14:30
What is the best strategy after 1st line in advanced BTC?

What is the best strategy after 1st line in advanced BTC?

Dr. Mervat Mahrous

14:30-14:50

Discussion

Moderator: Waleed Selwi

Panel: Fahed Ibn Shamsa,  Kanaan Alshemari,  Ashwaq Aolayan,  Mervat Mahrous

14:50-15:10

Lunch & Prayer

Session IV: lung cancer

15:10-15:30
Treatment of advanced ALK-positive NSCLC: Frontline and beyond

Treatment of advanced ALK-positive NSCLC: Frontline and beyond

Dr. Abdullah Altwergi

15:30 –15:50
Advanced SCLC: are we making real progress?

Advanced SCLC: are we making real progress?

Dr. Ahmed Alwabari

15:50-16:10
Management of new targetable mutations in advanced NSCLC

Management of new targetable mutations in advanced NSCLC

Dr. Emad Tashkandi

16:10-16:30

Discussion

Moderator: Walid Bahaj

Panel: Emad Tashkandi   ,  Ahmed Alwabari,  Abdullah Altwergi